Project Grant R41DA048689

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded a $524,774 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Johns Hopkins University to validate the Faceted Opioid Research Craving Assessment for Substance Use Treatment (FORCAST) as a patient-reported outcome drug development tool. The primary objectives of this 2-year project are to: 1) test and validate the factor structure of the FORCAST...

This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...

The University of Pittsburgh is receiving a $488,334 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to implement and evaluate a shared decision-making (SDM) approach in Opioid Treatment Programs (OTPs) for the treatment of opioid use disorder. The objective is to adapt and test the impact of Implementation Facilitation (IF), a bundle of preparation, implementation, and sustainment strategies, on supporting...

The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $591,752 Project Grant to Oprems LLC to develop a digital platform for electronic screening to identify the risk of opioid misuse and overdose. The project aims to integrate the tools and processes from Oprems' existing paper-based "ONE (Opioid and Naloxone Education)" program into a tablet-based digital platform. This digital platform will be used to consistently...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...

This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) provides $1,093,394 to the University of Illinois to develop the "CHICAGO DATA-DRIVEN OUD SCREENING, ENGAGEMENT, TREATMENT AND PLANNING (C-DOSETAP) SYSTEM". The two-year project aims to leverage machine learning, prescription data, and patient-reported measures to assess and address opioid use disorder (OUD) risk and associated health disparities on...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, will evaluate the benefits of a hand-held, automated, personalized oral liquid dispensing system for take-home methadone medication management for patients with opioid use disorder (OUD). The $326,410 award, with a performance period from June 1, 2025 to May 31, 2026, will support a clinical program delivered by Berkshire Biomedical Corporation. The project aims to...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $823,809 to the University of Pittsburgh to develop and validate a suite of multidimensional measures of access to Medications for Opioid Use Disorder (MOUD) across U.S. states and the District of Columbia. The primary objectives are to: Create a Small Area Multidimensional MOUD Access (SAMMA) measure suite using public data sources. Validate and...

The National Institute on Drug Abuse (NIDA) awarded a $2,729,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Rhode Island. The purpose of this 2-year award, with a start date of September 15, 2024, is to rigorously develop and evaluate a mobile health intervention for adults with co-occurring opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) during community re-entry after residential OUD treatment. The proposed mobile app...